| Kings Daughters Medical Center | |
|
2201 Lexington Ave Ashland KY 41101-2843 | |
| (606) 408-4000 | |
| (606) 408-7426 |
| Full Name | Kings Daughters Medical Center |
|---|---|
| Speciality | General Acute Care Hospital |
| Location | 2201 Lexington Ave, Ashland, Kentucky |
| Authorized Official Name and Position | Kristie Whitlatch (CEO) |
| Authorized Official Contact | 6064084401 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Kings Daughters Medical Center 2201 Lexington Ave Ashland KY 41101-2843 Ph: (606) 408-4000 | Kings Daughters Medical Center 2201 Lexington Ave Ashland KY 41101-2843 Ph: (606) 408-4000 |
| NPI Number | 1851346720 |
|---|---|
| Provider Enumeration Date | 05/22/2006 |
| Last Update Date | 08/20/2020 |
| Certification Date | 08/20/2020 |
| Medicare PECOS PAC ID | 7719882521 |
|---|---|
| Medicare Enrollment ID | O20040205001138 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851346720 | NPI | - | NPPES |
| 4710503 | Medicaid | OH | |
| 2373711 | Medicaid | OH | |
| 65923302 | Medicaid | KY | |
| 65940843 | Medicaid | KY | |
| 78900958 | Medicaid | KY | |
| 01012871 | Medicaid | KY | |
| 2255376 | Medicaid | OH |
| Provider Name | Charles Conley |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1386616373 PECOS PAC ID: 2062494016 Enrollment ID: I20040603000287 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Kimberly Sue Umhoefer |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1225140007 PECOS PAC ID: 7618943341 Enrollment ID: I20040907000016 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Rita Sue Roberts |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1013964931 PECOS PAC ID: 1850327123 Enrollment ID: I20050711000024 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Pho M Nguyen |
|---|---|
| Provider Type | Practitioner - Interventional Radiology |
| Provider Identifiers | NPI Number: 1447217328 PECOS PAC ID: 2062415201 Enrollment ID: I20060809000094 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Teresa Renee Tenpenny |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1144207499 PECOS PAC ID: 5597762112 Enrollment ID: I20061024000539 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Jennifer K Glockner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013979483 PECOS PAC ID: 3375646995 Enrollment ID: I20070319000644 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Tony K Virgin |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1669568044 PECOS PAC ID: 6305805433 Enrollment ID: I20090305000410 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Zachary Duane Underwood |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1386893840 PECOS PAC ID: 7719024199 Enrollment ID: I20091019000215 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Julia A Gilbert |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306171624 PECOS PAC ID: 5395882104 Enrollment ID: I20091028000177 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Ronald Arrick |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1104816859 PECOS PAC ID: 6709931728 Enrollment ID: I20091210000187 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Kevin W Kammler |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1710977400 PECOS PAC ID: 1355481052 Enrollment ID: I20091210000209 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Roy Aaron Adams |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629053251 PECOS PAC ID: 1254406150 Enrollment ID: I20091210000734 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | George E Esham |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1912995812 PECOS PAC ID: 1456491778 Enrollment ID: I20091217000568 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Jane Strader |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629272901 PECOS PAC ID: 2769677129 Enrollment ID: I20101115000268 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Matthew Allan Hensley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1073820205 PECOS PAC ID: 2163616103 Enrollment ID: I20101115000416 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Alisha Renee Hightower |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659670966 PECOS PAC ID: 0042494916 Enrollment ID: I20110419000041 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Charles A Gilliland |
|---|---|
| Provider Type | Practitioner - Sports Medicine |
| Provider Identifiers | NPI Number: 1366646192 PECOS PAC ID: 5799955324 Enrollment ID: I20110928000872 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Evan F Condee |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1952593998 PECOS PAC ID: 6901098912 Enrollment ID: I20111215000626 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Donald Morris Ramey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154604783 PECOS PAC ID: 2769656289 Enrollment ID: I20111229000738 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Tricia M Eichenlaub |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1467658518 PECOS PAC ID: 8527249234 Enrollment ID: I20120302000215 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Rachel A Cordle |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306170436 PECOS PAC ID: 7113065293 Enrollment ID: I20120413000429 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | John Mollineaux |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1932416948 PECOS PAC ID: 1153507876 Enrollment ID: I20120821000486 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Hassan R Abul Khoudoud |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1033255112 PECOS PAC ID: 3274678461 Enrollment ID: I20121030000480 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Paul W Lewis |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1780754028 PECOS PAC ID: 1759373533 Enrollment ID: I20130305000168 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Tina Marie England |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1760728679 PECOS PAC ID: 5991940298 Enrollment ID: I20130313000567 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Kevin M Wolfe |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003151150 PECOS PAC ID: 7113166711 Enrollment ID: I20130611000613 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Stephen Matthew Perkey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356658488 PECOS PAC ID: 1759524721 Enrollment ID: I20131018001204 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Cherri Lynn Sewell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407287923 PECOS PAC ID: 4385872282 Enrollment ID: I20140123001153 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Heather A Dailey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356773196 PECOS PAC ID: 6608006713 Enrollment ID: I20140310001949 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Elisabeth A Vest |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1023279213 PECOS PAC ID: 7911068838 Enrollment ID: I20140612001163 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Jerod C Walker |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1952684227 PECOS PAC ID: 1355560137 Enrollment ID: I20140909001431 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Paula K Larsen |
|---|---|
| Provider Type | Practitioner - Preventive Medicine |
| Provider Identifiers | NPI Number: 1003852955 PECOS PAC ID: 4981928637 Enrollment ID: I20150128001964 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Tammy L Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144639519 PECOS PAC ID: 6901120583 Enrollment ID: I20150131000129 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Haley J Bowden |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639575384 PECOS PAC ID: 1355666835 Enrollment ID: I20150203001824 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Thuy N Nguyen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1770842569 PECOS PAC ID: 4486961919 Enrollment ID: I20150916002055 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Lora L Stone |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437520673 PECOS PAC ID: 6002126521 Enrollment ID: I20151112000559 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Andrea Deserae King |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376916361 PECOS PAC ID: 8921309618 Enrollment ID: I20151222002641 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Traci Lynn Boyd |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245594811 PECOS PAC ID: 6709034325 Enrollment ID: I20160113002629 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Thomas Thomas |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831296250 PECOS PAC ID: 7517057557 Enrollment ID: I20160128001737 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Christopher Keeton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1316037740 PECOS PAC ID: 6406949494 Enrollment ID: I20160418002396 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Amber Dawn Stephens |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801259395 PECOS PAC ID: 2264731124 Enrollment ID: I20160427000324 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Sarah Rachel Fox |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114371648 PECOS PAC ID: 2163712035 Enrollment ID: I20160606000664 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Evan Patrick Seagraves |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265827844 PECOS PAC ID: 8628389004 Enrollment ID: I20160628002537 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Matthew B Harper |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1568783744 PECOS PAC ID: 2163742834 Enrollment ID: I20160901002633 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Leonard Herbert Otworth |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1841678109 PECOS PAC ID: 8820301203 Enrollment ID: I20161118000973 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Corey Dean Frasier |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184053563 PECOS PAC ID: 1658508510 Enrollment ID: I20170313002040 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Corey Danielle Webb |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265985584 PECOS PAC ID: 6901188986 Enrollment ID: I20170501000446 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Emily Anne Fuhrmann |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265949457 PECOS PAC ID: 1557621216 Enrollment ID: I20180129001837 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Barbara Collier Hale |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1073982591 PECOS PAC ID: 0648580209 Enrollment ID: I20180207002203 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | James Derrick Mills |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1366941106 PECOS PAC ID: 6507128493 Enrollment ID: I20180312001529 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Whitney A Ball |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386153179 PECOS PAC ID: 2163797440 Enrollment ID: I20180405001241 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Wanda Marie Poplin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1346797982 PECOS PAC ID: 4183912116 Enrollment ID: I20180430001439 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Bindyaben Ambubhai Patel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912484213 PECOS PAC ID: 4385995117 Enrollment ID: I20180918003262 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Ryan Thomas Faulkner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356829147 PECOS PAC ID: 9537410451 Enrollment ID: I20180919003519 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Mittra Esmaeili |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1114399474 PECOS PAC ID: 0840538914 Enrollment ID: I20190214002590 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Michael Alan Moore |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376089557 PECOS PAC ID: 3072874528 Enrollment ID: I20190405002358 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Kristina Wilburn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194375386 PECOS PAC ID: 9537595863 Enrollment ID: I20200205002289 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Leah Chicunque |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1730612409 PECOS PAC ID: 0941624860 Enrollment ID: I20200723002741 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Corey Lynn Bentley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1699385690 PECOS PAC ID: 7416359674 Enrollment ID: I20210709001749 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Whitney Rowe |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902395528 PECOS PAC ID: 4082969662 Enrollment ID: I20210819002968 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Emad Hamid |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1457553588 PECOS PAC ID: 7618021999 Enrollment ID: I20210903002783 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Isna Khan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1316432529 PECOS PAC ID: 1153674262 Enrollment ID: I20210923000826 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Amanda M Romesberg |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1780064980 PECOS PAC ID: 8426471772 Enrollment ID: I20211028000728 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Tori Scott |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124635446 PECOS PAC ID: 8921490913 Enrollment ID: I20220125002134 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Charles Mccormick |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710462395 PECOS PAC ID: 5597009837 Enrollment ID: I20220210002657 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | James Daniel Whaley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588308951 PECOS PAC ID: 7517346406 Enrollment ID: I20220623001932 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Erica Kaitlyn Schuster |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1477014322 PECOS PAC ID: 4587046420 Enrollment ID: I20220809001823 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Rhonda Crawford |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1467468397 PECOS PAC ID: 2365444114 Enrollment ID: I20220811001395 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Heather Jan Matthies |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457794646 PECOS PAC ID: 4880834472 Enrollment ID: I20220926002206 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Dhirenkumar Desai |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1366519498 PECOS PAC ID: 9931116860 Enrollment ID: I20221025000781 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Mayola Boykin |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1104995091 PECOS PAC ID: 6709814049 Enrollment ID: I20221027002830 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Scott Moore |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1558414441 PECOS PAC ID: 4082765110 Enrollment ID: I20221110002882 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Erik Fraley |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1609822584 PECOS PAC ID: 8123023462 Enrollment ID: I20221114000193 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Allyson Paige Applegate |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861103939 PECOS PAC ID: 5395116347 Enrollment ID: I20230301001326 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Daniel Nathan Laxton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1932836640 PECOS PAC ID: 7416320510 Enrollment ID: I20230310000175 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Tracy Jean Ferguson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639889199 PECOS PAC ID: 5496120339 Enrollment ID: I20230407000660 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Casey Burke |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1649668476 PECOS PAC ID: 3173826195 Enrollment ID: I20230619000756 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Kenneth W Brown |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1497384507 PECOS PAC ID: 0547690943 Enrollment ID: I20230811002185 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Rachel Ann Staker |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1164051926 PECOS PAC ID: 0446681035 Enrollment ID: I20230815002240 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Paul Matharoo |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1689835332 PECOS PAC ID: 9234395591 Enrollment ID: I20231012003372 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Bradley Wells |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1427202621 PECOS PAC ID: 4385884881 Enrollment ID: I20231107002839 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
| Provider Name | Garrick Sherman |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1093923666 PECOS PAC ID: 7517010127 Enrollment ID: I20231220003394 |
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
News Archive
AQUAGOLD International (PINKSHEETS: AQUI), a global distributor of premier Canadian spring water products, announced today that the company's CEO, Domingo M. Silvas III, is traveling to China to meet with Marco Hassoun and York Tang, two of the original founders of AQUAGOLD. Messrs. Hassoun and Tang currently oversee the company's operations in China.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
In Switzerland, more than 30,000 different substances are used on a daily basis in innumerable products - pharmaceuticals, cosmetics, cleaning agents or industrial chemicals.
› Verified 8 days ago
Lighthouse Professional Counseling Services, Pllc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1100 Our Lady's Way Ste 219, Ashland, KY 41101 Phone: 606-834-0020 Fax: 606-834-0049 | |
A Center 4 Change Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5900 Us Highway 60 West, Suite B, Ashland, KY 41102 Phone: 606-393-5586 | |
Interhope Counseling Services, Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 10730 Midland Trail Dr., Ashland, KY 41102 Phone: 606-928-0150 Fax: 606-929-5965 | |
River Cities Neurology, P.s.c Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 700 St Christopher Dr, Med Bldg 3 Ste 102, Ashland, KY 41101 Phone: 606-833-0876 Fax: 606-833-0916 | |
A Center 4 Change Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 5900 Us 60 W, Suite B, Ashland, KY 41101 Phone: 606-393-5586 | |
Elite Behavior Health Services, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1100 Our Ladys Way Ste 213, Ashland, KY 41101 Phone: 606-388-4911 Fax: 606-388-4913 | |
Wilma Castro, Md, Psc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 617 23rd St, Suite 12, Ashland, KY 41101 Phone: 606-326-1557 Fax: 606-326-1570 |